Aimmune Therapeutics Inc (NASDAQ:AIMT) Expected to Post Earnings of -$0.91 Per Share

Brokerages forecast that Aimmune Therapeutics Inc (NASDAQ:AIMT) will announce earnings per share (EPS) of ($0.91) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.86). Aimmune Therapeutics also posted earnings of ($0.91) per share in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($3.77) per share for the current year, with EPS estimates ranging from ($4.15) to ($3.49). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.93) per share, with EPS estimates ranging from ($3.52) to ($2.39). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.07.

AIMT has been the subject of several research reports. Wedbush cut their price objective on shares of Aimmune Therapeutics from $80.00 to $76.00 and set an “outperform” rating for the company in a research report on Tuesday, March 19th. BidaskClub downgraded shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald set a $45.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, February 28th. Finally, Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $50.50.

NASDAQ:AIMT traded up $0.03 during mid-day trading on Wednesday, hitting $19.78. The stock had a trading volume of 298,419 shares, compared to its average volume of 571,406. Aimmune Therapeutics has a twelve month low of $19.25 and a twelve month high of $36.12. The company has a market capitalization of $1.24 billion, a P/E ratio of -5.39 and a beta of -0.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65.

A number of hedge funds have recently modified their holdings of the business. Proficio Capital Partners LLC acquired a new stake in shares of Aimmune Therapeutics in the fourth quarter valued at approximately $96,000. Legal & General Group Plc increased its stake in Aimmune Therapeutics by 29.1% in the fourth quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 4,123 shares during the last quarter. Norges Bank bought a new position in Aimmune Therapeutics in the fourth quarter valued at approximately $6,035,000. Fiera Capital Corp increased its stake in Aimmune Therapeutics by 55.2% in the fourth quarter. Fiera Capital Corp now owns 89,053 shares of the biotechnology company’s stock valued at $2,130,000 after acquiring an additional 31,686 shares during the last quarter. Finally, Pearl River Capital LLC bought a new position in Aimmune Therapeutics in the first quarter valued at approximately $28,000. Hedge funds and other institutional investors own 76.13% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: What defines an oversold asset?

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.